5//SEC Filing
Nelson Christopher M. 5
Accession 0001493152-22-004619
CIK 0001310527other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:58 PM ET
Size
14.7 KB
Accession
0001493152-22-004619
Insider Transaction Report
Form 5
Nelson Christopher M.
DirectorCEO
Transactions
- Purchase
Preferred Series B Stock
2021-01-22$20000.00/sh+20$400,000→ 20 total - Other
Series E-1 Preferred Shares
2021-12-06−850→ 0 total - Award
Common Stock
2020-10-25+423,609→ 3,307,552 total - Award
Series E-1 Preferred Shares
2020-12-30+850→ 0 totalExercise: $0.00→ Common Stock (850,000 underlying) - Other
Common Stock
2021-12-06+2,883,943→ 2,883,943 total - Award
Options to buy common stock
2021-08-24+115,000→ 115,000 totalExercise: $0.36Exp: 2031-08-23→ Common Stock (115,000 underlying)
Footnotes (4)
- [F1]Pursuant to reclassification exempt tunde Rule 16b-7, each share of Series E-1 Preferred Stock was reclassified into and exchanged for shares of Common Stock of the Issuer under the terms of Exchange Agreement and Plan of Reorganization as filed with the SEC.
- [F2]Shares acquired upon conversion of deferred salary and earned bonus.
- [F3]The option vests semi-annually in two equal installments beginning on 02/24/2022.
- [F4]Series E-1 Preferred Stock was convertible at any time at the discretion of the holder at a ratio of 1000 shares of Common Stock per Series E-1 Preferred Stock.
Documents
Issuer
QSAM Biosciences, Inc.
CIK 0001310527
Entity typeother
Related Parties
1- filerCIK 0001529012
Filing Metadata
- Form type
- 5
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 9:58 PM ET
- Size
- 14.7 KB